The basic helix-loop-helix transcription factor Olig1 promotes oligodendrocyte maturation and is required for myelin repair. We characterized an Olig1-regulated G protein-coupled receptor, GPR17, whose function is to oppose the action of Olig1. Gpr17 was restricted to oligodendrocyte lineage cells, but was downregulated during the peak period of myelination and in adulthood. Transgenic mice with sustained Gpr17 expression in oligodendrocytes exhibited stereotypic features of myelinating disorders in the CNS. Gpr17 overexpression inhibited oligodendrocyte differentiation and maturation both in vivo and in vitro. Conversely, Gpr17 knockout mice showed early onset of oligodendrocyte myelination. The opposing action of Gpr17 on oligodendrocyte maturation reflects, at least partially, upregulation and nuclear translocation of the potent oligodendrocyte differentiation inhibitors ID2/4. Collectively, these findings suggest that GPR17 orchestrates the transition between immature and myelinating oligodendrocytes via an ID protein-mediated negative regulation and may serve as a potential therapeutic target for CNS myelin repair.
a r t I C l e S Myelination by oligodendrocytes is essential for the normal function of the vertebrate CNS. Demyelination or dysmyelination disrupts saltatory nerve conduction, leading to axonal degeneration and neurological disabilities associated with acquired and inherited disorders such as multiple sclerosis and leukodystrophies 1, 2 . The molecular mechanisms underpinning oligodendrocyte myelination and remyelination after injury are poorly understood. In rodents, oligodendrocyte precursor cells (OPCs) initially form during embryonic stages, but they do not generate myelin-producing oligodendrocytes until perinatal stages 3 . This probably reflects a highly coordinated process of myelination, in which positive and negative factors modulate the timing of oligodendrocyte maturation with final myelination of axons being actively opposed until all neuronal components of the developing CNS are in place.
Extracellular signals and intracellular timers, including oligodendrocyte differentiation inhibitors (for example, ID2 and ID4) 4, 5 and cell cycle inhibitors (p21, p27 and p57) [6] [7] [8] , have been shown to regulate oligodendrocyte maturation. Several receptor-mediated signaling pathways have been found to be critical for oligodendrocyte differentiation/myelination, including signaling mediated by Notch, BMP, neuregulin/ErbB2 and Lingo-1 (refs. [9] [10] [11] [12] [13] [14] . However, signaling mechanisms that mediate the operation of intracellular inhibitors or timers for the transition from immature to mature myelinating oligodendrocytes remain elusive. The observation that OPCs are present in demyelinating multiple sclerosis lesions, but fail to differentiate into mature oligodendrocytes 15, 16 , suggests that the remyelination process is blocked at a premyelinating stage in demyelinating lesions.
Thus, identification of critical regulators that inhibit myelination/ remyelination could facilitate the development of therapeutic targets for myelin repair in CNS demyelinating diseases.
The basic helix-loop-helix (bHLH) transcription factors Olig1 and 2 are important for oligodendrocyte myelination and remyelination [17] [18] [19] [20] [21] . Olig2 directs multipotent neural stem/progenitors to become lineage-restricted OPCs and Olig1 promotes maturation of oligodendrocytes in the developing CNS and is required for repair of demyelinated lesions in a murine model of multiple sclerosis 18, 19, 22 . Using transcriptome profile analysis of Olig1 -/-CNS 19 , we identified an oligodendrocyte lineage specific G protein-coupled receptor, GPR17. By analyzing Gpr17-overexpressing transgenic and Gpr17 knockout mice, we found that Gpr17 negatively regulates oligodendrocyte differentiation and myelination in vitro and in vivo. Our results suggest that GPR17 functions as a potent negative regulator for oligodendrocyte myelination, at least in part, via inducing nuclear localization of differentiation inhibitors ID2 and 4 and opposing Olig1 function.
RESULTS

Identification of oligodendrocyte lineage-specific GPR17
To identify the factors that may regulate oligodendrocyte myelination, we screened for genes that were downregulated in the optic nerves of myelination-deficient Olig1 -/mice using differential display 23 and microarray analysis ( Supplementary Table 1 ). Among the genes that were downregulated or absent in Olig1 mutants, Gpr17 expression was reduced approximately 232-fold, as determined by gene chip a r t I C l e S microarray analysis. Northern blot analysis ( Fig. 1a) indicated that Gpr17 was essentially absent from Olig1 -/brains. Multiple-tissue northern blot analysis showed that Gpr17 was restricted to the rodent CNS ( Fig. 1b) . Mouse Gpr17 encoding a 339 amino acid-residue protein with typical rhodopsin P2Y type-seven transmembrane motifs 24 was highly conserved among vertebrate species (Supplementary Fig. 1 ).
In the spinal cord, expression of Gpr17 was initially detected in the ventral ventricular zone at embryonic day 15.5 (e15.5; Fig. 1c ), which coincided with the appearance of a myelin gene, Plp1 (Fig. 1d) . At the late embryonic stage e18.5, Gpr17 was expressed throughout the gray and lateral white matter ( Fig. 1e) . In contrast, Gpr17 was not observed in peripheral Schwann cells in the dorsal root ganglion ( Fig. 1c,d) .
At P14, Gpr17-positive cells were enriched in CNS white-matter tracts ( Fig. 1f-k) . We also detected them in gray-matter regions ( Fig. 1i-j) . To define the identity of Gpr17-positive cells, we carried out double in situ hybridization of Gpr17 with markers for oligodendrocytes or their precursors. Approximately 79% of Gpr17-positive cells expressed Plp1 in the corpus callosum and cortex at postnatal day 14 (P14; Fig. 1g and Supplementary Fig. 2) , whereas a subset of them (approximately 21%) expressed the OPC marker Pdgfra ( Fig. 1h and Supplementary Fig. 2 ). Thus, these data suggest that Gpr17 is primarily, if not only, expressed in cells of the oligodendrocyte lineage. Consistent with its oligodendrocyte-specific expression, Gpr17 was essentially undetectable in CNS regions of Olig1 -/mutants ( Fig. 1l-n) .
Gpr17 is downregulated in mature oligodendrocytes
In the developing spinal cord, the number of Gpr17-positive cells appeared to increase from P0 to P7 ( Fig. 2a,b) , as did the number of Olig2-positive cells ( Fig. 2) . At P14, the number of Gpr17-positive cells in the white matter was reduced compared with that at P7 ( Fig. 2) . Notably, the number of Gpr17-positive cells decreased markedly, beginning at P21 ( Fig. 2d) , the peak period of myelinogenesis 25 . They were barely detectable in adulthood ( Fig. 2e) , in contrast with the continuous presence of Olig2-or Olig1-expressing cells ( Fig. 2i,j, Supplementary Fig. 3 and data not shown). This agedependent reduction of Gpr17 expression was further confirmed by quantitative real-time PCR (qRT-PCR) and western blot analyses ( Fig. 2k,n) , suggesting that Gpr17 was downregulated during terminal oligodendrocyte maturation. In contrast, expression of the mature oligodendrocyte markers Mbp and CC1 was highest at P21 and persisted to adulthood ( Fig. 2l and data not shown).
To determine whether Gpr17 expression can be directly regulated by Olig1, we transfected adult hippocampus-derived neural stem/ progenitors (HCN) with Olig1 and allowed them to differentiate into oligodendrocytes in the presence of IGF-1 (ref. 26) . Consistent with the idea that Olig1 promotes oligodendrocyte differentiation, we observed an increase of myelin (Mbp) gene expression in Olig1transfected cells, whereas the level of Gpr17 was significantly reduced (P = 0.0002; Fig. 2o ). We obtained similar results from Olig2-transfected cells ( Fig. 2o) . To understand the molecular basis of Olig1mediated repression of Gpr17, we then asked whether Olig1 could directly bind to the E-box consensus sequence (CAN NTG) in the upstream regulatory region of Gpr17 (Fig. 2p) . Chromatin immunoprecipitation (ChIP) was performed using an antibody to Myc-tagged Olig1 in transfected cells. We were able to amplify DNA fragments from the immunoprecipitated chromatin of Olig1-transfected cells with primers flanking the Gpr17 promoter region containing an E-box consensus sequence of the bHLH factor-binding motif, but not with primers for the region lacking the consensus sequence ( Fig. 2p) . Recruitment of Olig1 to the Gpr17 regulatory region containing the potential Olig1-binding site was increased in Olig1-transfected cells compared with vector-transfected cells (Fig. 2q) . These observations suggest that Olig1 can physically bind to the promoter of Gpr17 and negatively regulate its expression. a r t I C l e S of disease severity were dissected and processed for hemotoxylin and eosin staining analysis ( Supplementary Fig. 4 ). Inflammatory demyelinating lesions in the spinal cord were associated with prominent inflammatory infiltrate and Mbp expression was substantially reduced or absent ( Supplementary Fig. 4 ). In contrast with the scattered Gpr17-positive cells that we observed in controls, the number of Gpr17-positive cells markedly increased at the demyelinating lesion penumbra and/or in the lesion (Supplementary Fig. 4 ). Gpr17 expression was upregulated mainly in Olig1-positive cells and a subset of Pdgfra-positive OPCs in these lesions ( Supplementary Fig. 4 ). Thus, although downregulated in normal adult spinal cord, Gpr17 was reexpressed or upregulated in oligodendroglial cells after EAE-induced demyelinating injury. We carried out a qRT-PCR analyses of a cohort of human multiple sclerosis tissues and found that GPR17 expression was significantly increased in multiple sclerosis plaques as compared with white matter from non-neurological donor samples and normal-appearing white matter from multiple sclerosis donors (P < 0.01; Supplementary  Fig. 4 ). Thus, Gpr17 upregulation appears to be associated with demyelinating lesions induced by EAE and in multiple sclerosis.
Gpr17 is upregulated in demyelinating lesions in the CNS
Generation of Gpr17-overexpressing transgenic mice
The fact that Gpr17 expression was downregulated during active myelinogenesis and upregulated in demyelinating lesions raises the possibility that sustained expression of Gpr17 may negatively regulate oligodendrocyte myelination. To test this possibility, we generated transgenic mice with Gpr17 expression under the control of the Cnp1 promoter, leading to overexpression of Gpr17 in oligodendrocytes. We used a Myc tag to track Gpr17 transgene-expressing cells ( Supplementary Fig. 5 ). a r t I C l e S Expression of Gpr17 transcript and protein at P12 in the brains of transgenic mice was increased sixfold and threefold, respectively, compared with expression in control littermates, as determined by qRT-PCR and western blot analyses ( Supplementary Fig. 5 ). Myc was mainly detected in CC1-positive differentiated oligodendrocytes, but not in PDGFRα-positive OPCs in the transgenic mice ( Supplementary  Fig. 5 ). Multiple parallel processes along axons were visualized in Myc-GPR17-positive oligodendrocytes (Supplementary Fig. 5 ). In contrast, there was no overlap between Myc-GPR17 and the astrocyte marker GFAP or the pan-neuronal marker NeuN (Supplementary Fig. 5 ). Thus, these data indicate that the Gpr17 transgene was predominantly expressed in oligodendrocytes after the precursor stage.
Sustained expression of Gpr17 inhibits CNS myelination
Starting at postnatal week 2, Gpr17 transgenic mice began to experience generalized tremors, hindlimb paralysis and seizures (data not shown) that were reminiscent of those described for dysmyelinating mouse mutants 27 . The severity of tremors increases during postnatal week 3 and the majority of transgenic mice died around this period (Fig. 3a) . In Gpr17 transgenic mice, we observed a substantial reduction of Mbp and Plp1 expression in the cerebral white-matter region at P14 ( Fig. 3) . At P20, the reduction was much more severe ( Fig. 3c,e ), suggesting that Mbp expression decreases progressively with age. We confirmed the marked reduction of Mbp expression by immunostaining for MBP ( Fig. 3g) and western blot analysis a r t I C l e S ( Fig. 3h) . We stained for O4, which detects both pre-and differentiated oligodendrocytes, and found decreased immunoreactivity in the corpus callosum of transgenic mice as a result of the reduction of mature oligodendrocytes (Fig. 3i) . This observation suggests that Gpr17 overexpressing cells at the O4-positive stage do not differentiate further and/or undergo cell death.
Using qRT-PCR analysis to examine the expression of various myelin genes in the transgenic cortices, we observed a significant decrease of Mbp expression at P20, but not at the early developmental stage P7 (Fig. 3j,k) . Similar results were also obtained by quantifying Plp1-positive oligodendrocytes in the CNS (Supplementary Fig. 6 ).
In addition, we did not observe any detectable neuronal cell death and axonal loss in transgenic mice at P7 (data not shown).
Despite the deficiency in oligodendrocyte myelination, the number of OPCs formed in the transgenic brain was comparable to the control (Fig. 3l,m) . Furthermore, we did not detect significant alteration of OPC proliferation rates in the brain at different developmental stages, as determined by BrdU incorporation and Ki67 staining (P > 0.05; Fig. 3n and data not shown). These observations suggest that, despite initial formation of OPCs at an early postnatal stage, oligodendrocyte myelination is probably arrested at or after a pre-myelinating stage in Gpr17-overexpressing mice.
In contrast with the markedly reduced Mbp expression that we observed, expression of GFAP was upregulated in the CNS of transgenic mice (Fig. 3f,h) . However, the number of astrocytes marked by glutamine synthetase 28 was similar to that of the control (data not shown), indicating that there was an astroglial response to hypomyelination. Consistent with this notion, we observed a substantial number of Iba1-positive activated microglia/macrophages 29 with a hyper-ramified morphology in the transgenic brain (Supplementary Fig. 7) .
Myelination defects were also evident in the spinal cord of transgenic mice (Supplementary Fig. 8) . In contrast with the widespread CNS myelination deficiency, myelinogenesis appeared normal in the peripheral nervous system, including the sciatic nerve (data not shown), suggesting that the myelination defects caused by Gpr17 overexpression are specific to the CNS.
Myelinogenesis deficiency in Gpr17-overexpressing mice
In Gpr17 transgenic mice at P19, optic nerves were translucent compared with wild-type littermates (Fig. 4a) , indicating a lack of myelin sheaths. The number of myelinated axons was much reduced in CNS regions (Fig. 4b) . Ultrastructural analysis revealed that myelinogenesis was essentially absent in the optic nerve, corpus callosum and spinal cord (Fig. 4c) . This reduction of myelin thickness or absence of myelin was observed for all axons, independent of their caliber size. These results suggest that myelination is generally defective in the CNS with GPR17 overexpression in CNP-positive oligodendrocytes.
Although we observed a few myelinated axons in the optic nerve of transgenic mice at P14 (Fig. 4d) , they were hardly detectable at P21 (Fig. 4d) . This was correlated with a reduction in the number of mature oligodendrocytes and Mbp expression at later developmental stages (Fig. 4f,g) , suggesting a loss of mature myelinating oligodendrocytes after prolonged GPR17 overexpression.
Compared with morphologically normal oligodendrocytes surrounded by myelinated axons (arrows) in the optic nerve from wild-type mice (Fig. 4e ) a few oligodendrocytes in Gpr17 transgenic mice contained condensed chromatin mass and shrunken cytoplasm a r t I C l e S ( Fig. 4e) , a characteristic feature of cells undergoing apoptosis. In contrast, we did not detect oligodendrocyte death in age-matching wild-type mice. Thus, these observations suggest that sustained GPR17 overexpression in CNP-positive oligodendrocytes leads these cells to differentiation arrest and/or apoptotic cell death. Despite the deficits in mature oligodendrocytes, we did not observe substantial neuronal cell death (data not shown) and axonal loss, as detected by neurofilament immunostaining (Fig. 4h) .
Gpr17 overexpression inhibits oligodendrocyte maturation
To determine the effects of Gpr17 expression on oligodendrocyte differentiation in vitro, we transfected HCN progenitors 26 with Gpr17 expression vectors and control vectors carrying a nuclear-localized GFP 30 . At 3 d post-transfection, control transfected cells differentiated into mature oligodendrocytes with elaborated complex processes and expressed mature oligodendrocyte markers RIP, MBP and MOG (Fig. 5a) . In contrast, Gpr17-overexpressing cells had a simple bi-or tripolar morphology and did not express mature oligodendrocyte markers ( Fig. 5b) , suggesting that they were arrested at the precursor stage.
In light of the negative effects of Gpr17 on oligodendrocyte differentiation, we then examined whether Gpr17 overexpression could alter expression of potential oligodendrocyte differentiation inhibitors such as Id2, Id4, Hes5 and Tcf4/Tcf7l2 (refs. 4,5,14,31) . By qRT-PCR assay, we detected a significant increase of Id2, but not of Id4, Tcf4 or Hes5 (P = 0.003; Fig. 5c ). Notably, in contrast with cytoplasmic expression of ID2 in control-transfected cells (Fig. 5d) , ID2 appeared to translocate into the nucleus in the majority of Gpr17-transfected cells ( Fig. 5e and Supplementary Fig. 9 ). By The cells were collected and processed for co-immunoprecipitation with an antibody to ID2 or ID4. Immunoprecipitated proteins were subjected to western blot analysis for Olig1 as indicated. Scale bars represent 50 mm (a-e), 25 mm (g,h) and 50 mm (i,j).
a r t I C l e S fractionating the nuclear and cytoplasmic components of Gpr17-transfected cells, we observed predominantly nuclear accumulation of ID2 with a concomitant decrease in the cytoplasm (Fig. 5f) . As controls, Gpr17 overexpression had no effects on subcellular distribution of the nuclear-localized cAMP response element-binding protein (CREB) and the cytoplasmic-localized protein GAPDH (Fig. 5f) . Similarly, Gpr17 overexpression in HCN cells led to the nuclear translocation of ID4 (Supplementary Fig. 9 ). Thus, Gpr17 overexpression results in both an increase of Id2 and the nuclear translocation of ID2 and 4, which have been shown to inhibit OPC maturation 4, 5 .
We further examined the effect of Gpr17 overexpression in primary OPCs isolated from rat neonate cortices. The formation of complex MBP-positive cells among transfected cells was significantly reduced, from ~43% in the control to ~22% in Gpr17-transfected OPCs (>1,000 cell counts, P < 0.01). Gpr17-transfected cells appeared to have less or thinner processes ( Fig. 5) , suggesting that Gpr17 overexpression inhibits OPC maturation in vitro.
To define the differentiation potential of Gpr17-overexpressing cells, we prepared oligodendroglial-enriched cultures from embryonic cortices. Although we detected O4-positive pre-oligodendrocytes in the culture from transgenic embryos, they failed to fully differentiate into complex MBP-positive oligodendrocytes, in contrast with the formation of mature MBP-positive oligodendrocytes in wild-type cultures (Fig. 5i) . ID2 expression was observed in the cytoplasm of mature oligodendrocytes in wild-type culture, whereas it was detected in the nucleus of immature oligodendrocytes cultured from Gpr17 transgenic mice (Fig. 5j) .
Consistent with our in vitro results, we detected an upregulated in the expression of Id2 in the corpus callosum of transgenic mice (Supplementary Fig. 10) . To determine whether ID2 can associate with Olig1, and therefore block Olig1 function in Gpr17-overexpressing cells, we carried out co-immunoprecipitation assays with ID2 and Olig1 using oligodendroglial-enriched cultures from wild-type, Gpr17-overexpressing transgenic and Gpr17 -/mice. We observed that less Olig1 was pulled down by ID2 in co-immunoprecipitations of Gpr17 -/cells when compared with wild type, whereas a substantially higher amount of Olig1 was associated with ID2 in Gpr17-overexpressing cells (Fig. 5k) . A similar result was obtained in an ID4 and Olig1 co-immunoprecipitation pull-down assay (Fig. 5k) . These observations suggest that GPR17 induces nuclear localization of differentiation inhibitors such as a r t I C l e S ID2 and 4, which then inhibit oligodendrocyte maturation by sequestrating Olig1 through direct interactions.
Gpr17 -/mice have early onset of CNS myelination
To study the effects of the loss of function of Gpr17, we generated Gpr17 -/mice by homologous recombination in embryonic stem cells. Our targeting strategy deleted the entire Gpr17 coding region (Fig. 6a) .
The targeted allele was confirmed by Southern blotting and PCR analyses (Fig. 6b,c) . Histone 2b-fused GFP (h2b-GFP) was knocked into the Gpr17 locus to trace individual endogenous GPR17-expressing cells (Fig. 6a) .
Immunostaining of GFP and a battery of markers for oligodendrocyte lineage cells, astrocytes and neurons revealed that Gpr17 was restricted to the oligodendrocyte lineage ( Supplementary Fig. 11-14) , consistent with observations with mRNA in situ hybridization. Similarly, we detected GPR17 in PDGFRα-positive OPCs and MBP-positive mature oligodendrocytes in oligodendroglial cultures isolated from Gpr17 +/embryonic cortices (Supplementary Fig. 15 ). Consistent with a role for GPR17 in inhibiting maturation of oligodendrocytes, early and robust MBP expression was already detectable in the spinal cord of Gpr17 -/embryos at e17.5 (Fig. 6) . In contrast, MBP expression was barely detectable in the spinal cord of control embryos at this stage ( Fig. 6d) , despite a comparable formation of PDGFRα-positive OPCs and their proliferation rate between control and Gpr17 -/mice (Fig. 6f,g and Supplementary Fig. 16 ).
As the initiation of axonal myelination typically occurs at neonatal stages, we examined myelin formation at P3 by electron microscopy in the spinal cord, where myelination is relatively homogeneous and well characterized. We found a significant increase in the number of myelinated axons in Gpr17 -/mice compared with their wild-type littermates in the corresponding lateral white-matter region (P = 0.0082; Fig. 6h-j) , suggesting an early onset of CNS myelination in the absence of Gpr17.
We did not find a substantial increase in the number of myelinated axon fibers in the CNS of adult Gpr17 -/mice. The myelin g-ratio and the number of oligodendrocytes were comparable between wild-type and Gpr17 -/mice (data not shown). This may reflect that there are other regulators for the induction of myelination that can compensate for the loss of Gpr17 in adult mice.
To determine the differentiation capacity of Gpr17 -/progenitor cells in vitro, we cultured oligodendroglial progenitors from wild-type, Gpr17 +/and Gpr17 -/embryos 32, 33 . Gpr17 -/progenitors differentiated into MBP-positive or RIP-positive mature oligodendrocytes earlier than control cells (Fig. 6k-n and Supplementary Fig. 17 ). Despite the initial delay, wild-type and heterozygous precursors increasingly differentiated into oligodendrocytes over time and eventually reached the same level as Gpr17 -/precursors ( Fig. 6k-n) . Thus, in vitro and in vivo observations suggest that the loss of GPR17 function accelerates oligodendrocyte precursor differentiation and myelination.
DISCUSSION
GPR17 as a negative regulator of CNS myelination
A precise balance between activators and inhibitors is crucial for controlling the timing of myelination in the CNS under normal and pathological conditions 34, 35 . A common feature of demyelinated lesions is the differentiation block of oligodendrocyte precursors at a pre-myelinating stage 36, 37 . Identification and characterization of inhibitory signaling molecules may provide potential therapeutic targets for enhancing remyelination. Here, we identified a G protein-coupled receptor GPR17 that functions as a negative regulator for CNS myelinogenesis.
Gpr17 is restricted to oligodendrocyte-lineage cells in the CNS in a developmentally regulated manner. As with other inhibitory factors 38 , Gpr17 expression is downregulated and oligodendrocyte myelination begins as development progress. In vitro, Gpr17 overexpression not only blocked differentiation of neural progenitor cells into oligodendrocytes, but also inhibited terminal differentiation of primary OPCs. In transgenic mice, sustained Gpr17 overexpression in CNP-positive oligodendrocytes resulted in myelination arrest and oligodendrocyte loss. Conversely, Gpr17 deletion accelerated OPC maturation in vitro and led to an early onset of myelination in the developing CNS. Taken together, these data suggest that GPR17 acts to negatively regulate oligodendrocyte differentiation and myelination.
Gpr17 was identified as one of the genes that is downregulated in Olig1 -/mice. This is probably a result of a reduction of differentiated oligodendrocytes in Olig1 mutants, resulting in a decrease in the expression of many genes that are normally expressed in oligodendrocytes ( Supplementary Table 1 ). Nonetheless, overexpression of Olig1 repressed Gpr17 expression by directly binding to its regulatory region, indicating that Olig1 negatively regulated Gpr17 expression. Notably, the oligodendrocyte-restricted GPR17 expression described here and elsewhere 39 is not consistent with earlier reports that the majority of GPR17-positive cells are neurons 40, 41 . This discrepancy may reflect the specificity of the GPR17 antibodies used for immunohistochemistry in the earlier studies 41 . Our analyses of mRNA and a nuclear-localized GFP reporter for endogenous GPR17 expression clearly indicate that GPR17 was expressed predominantly, if not only, in oligodendrocyte-lineage cells in the CNS.
A negative regulatory loop modulates CNS myelination
Several potent regulators of the timing of oligodendrocyte differentiation have been identified, including the bHLH factors ID2, ID4 and Hes5 (refs. 4,5,14,31) , and cell-cycle inhibitors 7, [42] [43] [44] . The extracellular signals that control the operation of intracellular inhibitors or timers for oligodendrocyte maturation are not fully understood at this time. We observed that Olig1 promoted Mbp expression while repressing Gpr17 expression. Overexpression of Gpr17 inhibited oligodendrocyte differentiation and led to nuclear localization of ID2 and 4, powerful inhibitors of oligodendrocyte maturation 4, 5 . ID2 and 4 have been shown to physically interact with and sequester the bHLH factors Olig1 and Olig2 to block oligodendrocyte differentiation 14 . The fact that GPR17 overexpression increased nuclear translocation of ID2 and 4 and that they associated with Olig1 suggests that GPR17 signaling opposes the action of Olig1 and possibly its paralog Olig2 for oligodendrocyte differentiation through an ID protein-mediated negative regulatory loop (Supplementary Fig. 18 ). The phenotype of Gpr17 overexpression in transgenic mice is reminiscent of that of Olig1 -/mice with severe myelination deficits 19 . On the other hand, Gpr17 -/mice have accelerated oligodendrocyte differentiation and early onset of myelination. Thus, these gain-and loss-of-function studies suggest that GPR17 is an integral signaling component that controls the timing of oligodendrocyte differentiation and orchestrates the transition between immature and mature myelinating oligodendrocytes via, at least in part, ID2 and 4-mediated negative regulation.
Implications in CNS demyelinating diseases
Gpr17 transgenic mice with persistent Gpr17 overexpression in oligodendrocytes exhibit the stereotypic pathology of myelination disorders, with a failure of myelin sheath formation and reactive gliosis. We noted that Gpr17 was re-expressed or upregulated in demyelinating lesions in EAE and human multiple sclerosis plaques ( Supplementary  Fig. 4) . It is not clear whether upregulation of Gpr17 in demyelinating lesions is correlated with remyelination arrest in multiple sclerosis lesions. It will be of interest to determine whether activation of GPR17 a r t I C l e S signaling could inhibit remyelination by oligodendrocytes in the lesions. Conversely, GPR17 antagonists may promote remyelination.
The physiological ligands for GPR17 have not been fully elucidated. A recent in vitro study suggested that GPR17 responds to two classes of ligands, uracil nucleotides and the inflammatory lipid mediators cysteinyl-leukotrienes 41 . It remains of interest to identify and characterize the signals, such as molecules derived from axons or inflammatory mediators, which may activate GPR17 signaling to block oligodendrocyte maturation. Notably, knockdown of GPR17 by antisense technology or antagonists decelerated lesion progression in a rat brain focal ischemia model, suggesting that GPR17 has a pathological role during recovery after stroke 41 . Compared with intracellular transcriptional regulators, cell type-specific, G protein-coupled receptor-mediated signaling pathways are highly amenable to pharmaceutical modulation. Our data suggest that targeted inhibition of GPR17 receptor signaling, together with other treatments, might augment remyelination by immature oligodendrocytes following a variety of pathological insults.
METhODS
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quantitative SYBR green PCR mix (Applied Biosystems). The fold-enrichments were determined by the 2 -∆CT method, as previously described 49 . For primer sequences, we used region I forward 5′-CCA ACG TAA AGT AGC CAG TCC  TGG-3′ and reverse 5′-GCT GGT CAA CTC TAT TGT GAC CAG C -3′, and  region II forward 5′-AGG TAG CTT TCC AGG CTC TGA GTT-3′ and reverse  5′-AAC TCG GGA GAA ACA TGG CTG TTC- 
Analysis of human multiple sclerosis samples.
Tissue specimens from multiple sclerosis patients were obtained from the Human Brain and Spinal Fluid Resource Center (Veterans Affairs West Los Angeles Healthcare Center), which is sponsored by the National Institute of Neurological Disorders and Stroke, the National Institute of Mental Health, the National Multiple Sclerosis Society and the Department of Veterans Affairs. Frozen autopsy samples from ten multiple sclerosis patients and ten normal individuals were processed for total RNA using Qiagen RNeasy, with adjacent sections being processed for histology. For each donor with multiple sclerosis, samples included plaques, adjacent white matter and nearest gray matter; all samples were from frontal lobe.
Total RNA was assessed for quality by an Agilent Bioanalyzer and expression of GPR17 was measured by quantitative real-time RT-PCR using the ABI PRISM 7900HT sequence detection system (Applied Biosystems) and normalized to the expression of a housekeeping gene (HPRT). Two unique qPCR primer/probe sets (5′-3′) were used to determine relative expression of GPR17 cDNA and confirm expression patterns. All RNA was DNase treated (DNA-free, Ambion) before generation of cDNA using a Taqman reverse transcription kit (Applied Biosystems). Using 20 ng of total RNA equivalent cDNA, samples were subject to qPCR using 2× Taqman Universal Buffer (Applied Biosystems) with 200 µM forward and reverse primers and 900 µM probe with the following PCR conditions: 50 °C for 2 min, 95 °C for 10 min, 95 °C for 15 s and 60 °C for 1 min (40×). Each PCR reaction was run in triplicate for each biological sample included in the study.
Statistical analysis.
Results were analyzed for statistical significance using twotailed Student's t test and all error bars were expressed as s.d. Values of P < 0.05 were considered to be significant. Multiple comparisons were carried out using one-way analysis of variance analysis (ANOVA) with post-test: Newman-Keuls multiple comparison test.
